Nanosphere, Inc. (NSPH)
Lazard Capital Markets Healthcare Conference
November 13, 2012 08:00 AM ET
William P. Moffitt III - President and CEO
J. Roger Moody Jr., - PAO and CFO
Stephen Unger - Lazard Capital Markets
Stephen Unger - Lazard Capital Markets
Previous Statements by NSPH
» Nanosphere's CEO Discusses Q3 2012 Results - Earnings Call Transcript
» Nanosphere's CEO Discusses Q2 2012 Results - Earnings Call Transcript
» Nanosphere CEO Discusses Q3 2010 Results - Earnings Call Transcript
» Nanosphere, Inc. Q2 2010 Earnings Call Transcript
So we have a very strong two days plan for you guys. We have 23 companies here, 14 public, 9 are private in Life Science Tools and Diagnostics. Most of them are diagnostics, that’s in my opinion where the action is at least at the moment.
So planning new advance technologies into the clinical study. Our first presentation, I’m very happy to introduce is Nanosphere and today we have with us CEO, Will Moffitt and CFO, Roger Moody. And those are going to handle the presentation, maybe we will have a little bit of time for Q&A.
I do want to highlight one thing before we get started, we do have a [lunch] speaker today, I’m only introduced once, the keynote speaker Dr. Martin Kohn, who is the Chief Medical Officer – Medical Scientist, excuse me, for IBM Research and he just have let us walk in through super computing stuff and data crunching and all that and I think there is going to be a lot there to think about.
With that, I’m going to hand it over to Bill and again if we do have some time, we will do a little bit of Q&A. Thank you.
William P. Moffitt III
Thanks, Steve and thanks to everyone at Lazard for including us in the conference this year. It’s my pleasure to be here and review with you the story of Nanosphere. The regulatory forward-looking statements – statement we figured how to get 2,000 words on a single slide. Essentially I will translate this as anything I say is not based on fact or history is likely to come out different than what I might say.
The highlights of this Company are very intriguing and in fact to me personally and I think to all those who are invested in the Company, we have a very break through molecular diagnostics platform, the Verigene system is designed to enable much earlier detection of disease and guidance of therapies. We have the ability to do both nucleic acid or genetic tests in the system as well as ultra-sensitive protein and we demonstrated the possibility to do both on the same sample at the same time.
So it’s a very flexible system with a flexible format and designed to show a significant need in today’s marketplace. One of the leading edges of that significant need is the conversion of century old methods in microbiology to molecular methods, rather than growing bugs out on plated media over the course of a few days together result back to a physician on a critically old patient. Molecular methods, those are we’re bringing to the market in fact cut those days into hours and we will walk through an example of that here in just a few minutes.
There are significant upside in this Company beyond just display in microbiology or be at the microbiology play along to drive this Company to and through profitability with good strong healthy growth. But we will spend a couple of minutes at the end of the presentation talking about that upside opportunity in cardiovascular diagnostics.
We have been investing in parallel, if you will, over the last few years in both system functionality and development, as well as investing at a very broad menu to address the infectious disease market as well as the cardiovascular market. The assays that we have in infectious disease include respiratory virus, notably a blood stream infection, maybe the short cut term for that would be sepsis assay. It is the first ever cleared by the FDA; it was cleared at the end of June of this year. We have just commenced the marketing effort for that product. And we have others in the pipeline of C. difficile assay and enteric package and panel and the other half, if you will, the blood stream infection, which is a gram-negative half.
On the cardiovascular side, we’ve had in the market for sometime now, a Warfarin Metabolism assay for determining the appropriate induction dose for patients going on Coumadin. We’ve also had a thrombophilia panel, it’s an assay designed to determine whether or not the individual is predisposed for blood clots. Someone who is genetically wired have a stroke or heart attack much sooner in the life then otherwise they would have.
We have a Troponin assay that is in the stage of transferring from one platform to another, so we can get a high throughput model here on this assay and we have had in the FDA an assay for 2C19, it is an assay designed to assess drug therapy for drugs in a metabolize through the 2C19 genetic pathway, the most notable those probably will the number one in the thrombolytic and that’s Plavix. That assay was cleared by the FDA just a few days ago, press release went out here about 20 minutes ago on the clearance about assay. So we’re very pleased to have that in our portfolio now as well.